{
    "fund_name": "WisdomTree BioRevolution UCITS ETF - USD Acc",
    "type": "ETF",
    "ucits": true,
    "leverage": false,
    "derivatives": false,
    "swaps": false,
    "inverse": false,
    "replication_method": "physical",
    "complex_factors": [],
    "classification": "non-complex",
    "supporting_data": "The WisdomTree BioRevolution UCITS ETF is classified as non-complex under MiFID II regulations. The ETF uses physical replication to track the WisdomTree BioRevolution ESG Screened Index, which consists of equities involved in biotechnology and related sectors. There is no evidence of leverage, inverse strategies, or significant derivative usage beyond standard efficient portfolio management. The risk profile (SRRI 6) is primarily due to sector concentration rather than structural complexity. The fund's documentation explicitly states it uses physical replication and does not employ synthetic methods or complex financial instruments. While there are standard risks associated with equity investments and sector concentration, these do not meet the thresholds for complexity under MiFID II.",
    "confidence": 95,
    "risk_level": 6,
    "primary_reasoning": "The ETF uses physical replication of a straightforward equity index without leverage or complex derivatives, making it non-complex under MiFID II.",
    "counter_argument_consideration": "While the SRRI of 6 indicates higher risk, this is due to sector concentration in biotechnology rather than structural complexity. The use of repurchase agreements and stock lending for efficient portfolio management does not constitute complexity under MiFID II as these are standard practices for liquidity management in physically replicated ETFs."
}